Abstract
Expression of recombinant proteins in Escherichia coli (E. Coli) remains the most popular and cost-effective method for producing proteins in basic research and for pharmaceutical applications. Despite accumulating experience and methodologies developed over the years, production of recombinant proteins prone to aggregate in E. Coli-based systems poses a major challenge in most research applications. The challenge of manufacturing these proteins for pharmaceutical applications is even greater. This review will discuss effective methods to reduce and even prevent the formation of aggregates in the course of recombinant protein production. We will focus on important steps along the production path, which include cloning, expression, purification, concentration, and storage.
| Original language | English |
|---|---|
| Pages (from-to) | 236-246 |
| Number of pages | 11 |
| Journal | FEBS Letters |
| Volume | 588 |
| Issue number | 2 |
| DOIs | |
| State | Published - 21 Jan 2014 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- Aggregation analysis
- Aggregation suppressor
- Buffer condition
- Chaotrope
- Chaperone
- Fusion protein
- Induction condition
- Intrinsically disordered protein
- Intrinsically disordered region
- Kosmotrope
- Protein aggregation
- Protein concentration
- Protein storage
- Stabilizer
Fingerprint
Dive into the research topics of 'Production of prone-to-aggregate proteins'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver